药物涂层气球对冠状动脉再血管化的长期益处
Bernardo Cortese1,2, Sara Malakouti3, Waqas Mazhar3,4
1Fondazione Ricerca e Innovazione Cardiovascolare, Milan, Italy - bcortese@gmail.com.
Minerva cardiology and angiology
|December 21, 2023
概括
与旁路手术相比,释放药物的支架 (DES) 在治疗冠状动脉疾病方面存在局限性. 药物涂层气球 (DCB) 为长期结果提供了潜在的优势,目前正在进行的研究正在探索组合疗法.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 生物材料在医学中的应用
背景情况:
- 药物排泄支架 (DES) 是冠状动脉疾病 (CAD) 的首要治疗方法.
- 目前的DES在短期临床事件方面没有证明与冠状动脉旁路移植 (CABG) 相比的非劣势.
- 在长期随访中,DES与CABG相比,与目标血管再血管化的风险更高有关.
研究的目的:
- 审查当前药物释放支架 (DES) 的技术局限性.
- 突出使用药物涂层气球 (DCB) 进行皮肤穿透冠状动脉干预 (PCI) 对长期结果的潜在益处.
- 探索DCB-PCI与CABG相比的潜在非劣势.
主要方法:
- 文献综述和现有关于CAD中DES和DCB疗法的研究综合.
- 对临床结果的分析,包括目标血管再血管化和累积的临床事件.
- 讨论正在进行的混合疗法 (DCB+DES) 研究.
主要成果:
- 在实现长期疗效方面,DES表现出与CABG相比较的局限性.
- 药物涂层气球 (DCB) 在管理特定的CAD挑战方面表现有前途,例如静脉静脉复缩和小血管病变.
- 需要进一步的研究来评估DCB的长期表现和对CABG的非劣势.
结论:
- 由于DES的技术限制,需要探索替代或辅助疗法.
- DCB-PCI为改善CAD管理的长期结果提供了一个可行的选择.
- 混合DCB+DES治疗正在研究复杂的CAD病例,旨在匹配CABG的性能.
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
519
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
519
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
171
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
171